Encinitas, CANCT07227415Now EnrollingIRB Ready

Carcinoma, Renal Cell Clinical Trial in Encinitas, CA

Access cutting-edge carcinoma, renal cell treatment through this clinical trial at a research site in Encinitas. Study-provided care at no cost to qualified participants.

Sponsored by Pfizer

Quick Self-Assessment

See if you qualify for this Encinitas location

Preparing your pre-screening questions…

Expert Care in Encinitas

Access carcinoma, renal cell specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related carcinoma, renal cell treatment provided free

Apply for This Encinitas Location

Check if you qualify for this carcinoma, renal cell clinical trial in Encinitas, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Encinitas

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Encinitas site if eligible
  4. 4Begin participation

About This Carcinoma, Renal Cell Study in Encinitas

This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the study medicine, when given alone or with other anticancer medicines, and how this type of cancer responds to them. To join the study, participants must be adults; with locally advanced or metastatic RCC; who have not received treatment for their advanced kidney cancer. Participants will receive study medicine either alone or with other anticancer medicines. The medicine will be given through intravenous (IV) infusions, which means it will be injected directly into a vein. All treatments will take place at clinical study sites, where trained medical staff will take care of participants during and after each visit.

Sponsor: Pfizer

Who Can Participate

Inclusion Criteria

18 years of age or older at screening
Locally advanced (not amenable to curative surgery or radiation therapy) or metastatic RCC with diagnosis confirmed by histology/cytology
At least one measurable (as defined by the investigator) and untreated lesion
Adequate hematologic, hepatic, cardiac and renal function
No prior systemic therapy for RCC (immunotherapy after surgery is allowed if received \>12 months prior)
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
All International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) based risk categories

Exclusion Criteria

Participants may be excluded if they meet any of the following:
Known active brain lesions including leptomeningeal metastasis, brainstem, meningeal or spinal cord metastases or compression.
Clinically significant risk of haemorrhage or fistula
History of another malignancy within 3 years
History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
active autoimmune diseases requiring systemic treatment within the past 2 years
uncontrolled cardiac and other comorbidities within 6 months prior to the first dose
Major surgery or severe trauma within 4 weeks before the first dose, or planned major surgery during the study
History of severe bleeding tendency or coagulation dysfunction
History of oesophageal varices, severe ulcers, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess or acute gastrointestinal bleeding within 6 months prior to the first dose
Acute, chronic or symptomatic infections
Participants with history of immunodeficiency

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Encinitas?

Yes, this clinical trial (NCT07227415) has an active research site in Encinitas, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Carcinoma, Renal Cell Treatment Options in Encinitas, CA

If you're searching for carcinoma, renal cell treatment options in Encinitas, CA, this clinical trial (NCT07227415) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Encinitas research site is actively enrolling participants for this clinical trial. You'll receive care from experienced carcinoma, renal cell specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Ready to Join in Encinitas?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Encinitas, CA